Avacta Group PLC Affimer On-line Catalogue Launch (9209S)
September 30 2014 - 2:00AM
UK Regulatory
TIDMAVCT
RNS Number : 9209S
Avacta Group PLC
30 September 2014
30 September 2014
Avacta Group plc
("Avacta" or the "Group")
Affimer On-line Catalogue Launch
Avacta Group plc (AIM: AVCT), the global provider of proprietary
diagnostic tools, consumables and reagents for human and animal
healthcare, announces that Avacta Life Sciences has launched its
on-line catalogue of Affimer reagents. There are currently 40
products in the Affimer catalogue.
In May of this year, Avacta raised GBP10m through a placing of
ordinary shares with support from existing shareholders as well as
new investors. This money was raised to accelerate the
commercialisation of Affimers by investing in the scale up of
product development, production and commercial operations. The sale
of Affimer reagents through an on-line catalogue is one of the
major revenue opportunities for Affimers set out at the time of the
placing. A further revenue opportunity is to provide bespoke
Affimer reagents for life sciences customers in academia and
industry by screening Avacta's library of Affimers. The Company is
in the process of expanding its business development teams for the
US and European markets to deliver this service to market.
Affimers are engineered alternatives to antibodies and have been
designed to address many of the negative performance issues
currently experienced with antibodies; namely, the time taken to
generate a new antibody, specificity and batch to batch variation
which can limit their application in many circumstances.
Furthermore, there are many targets to which antibodies simply
cannot be developed for a range of reasons. The discovery of one
such set of targets, referred to as "ubiquitylation" which is an
important pathway in many diseases, resulted in the award of the
Nobel prize for chemistry over a decade ago and yet, despite the
importance of this area of research in drug development and
diagnostics, the major antibody companies have struggled to
generate antibodies that bind to these targets. The on-line
catalogue has a number of Affimers that bind to targets involved in
ubiquitylation as well as Affimers that replace some common
workhorse antibodies, both representing prime revenue generating
targets.
Over the coming months and years the Group intends to grow the
catalogue to provide a comprehensive and powerful toolkit for the
detection of disease, discovery and validation of new disease
biomarkers and drug targets and a range of other applications
across life sciences research and industrial development.
Alastair Smith, Chief Executive of Avacta said: "We are very
excited about the new online catalogue that makes Affimers
available to our customers off the shelf for the first time.
The launch of the catalogue with this initial product set is a
demonstration of our capability to deliver Affimers on a commercial
basis and is an important first part of the execution of our much
wider plan. The processes we have put in place are capable of
delivering a vast range of Affimers to add to our catalogue over
time.
Our capabilities now enable us to access the market with bespoke
Affimers for customers where we are seeing very strong interest in
our technologies from major customers."
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tim Sykes, Chief Financial Officer
Numis Securities Limited Tel: +44 (0)
Michael Meade / Freddie Barnfield 207 260 1000
- Nominated Adviser www.numiscorp.com
James Black - Corporate Broking
Media Enquiries Tel: +44 (0)
Walbrook PR Ltd 207 933 8780
Anna Dunphy / Mike Wort avacta@walbrookpr.com
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative
technologies, consumables and reagents for the life science
markets, from drug discovery to diagnostics. Avacta operates
through three divisions:
Avacta Analytical High throughput analysis instrument,
www.avactaanalytical.com Optim, to help reduce the cost and
risk of drug development.
--------------------------------------- -----------------------------------------
Avacta Animal Health Veterinary diagnostics reference
www.avactaanimalhealth.com laboratory and diagnostic kit provider.
--------------------------------------- -----------------------------------------
Avacta Life Sciences Novel non-antibody affinity reagents
www.avactalifesciences.com called Affimers, with a wide range
of Life Science applications in
diagnostics, drug and biomarker
discover and biotech research and
development.
--------------------------------------- -----------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUGWBUPCGQB
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024